Zealand Pharma A/S
ZLDPF
$40.99
-$0.01-0.02%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15,364.41% | 12,416.28% | 2,483.34% | -84.05% | -81.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15,364.41% | 12,416.28% | 2,483.34% | -84.05% | -81.87% |
| Cost of Revenue | -89.34% | -93.56% | -117.76% | -78.44% | -33.72% |
| Gross Profit | 17,545.36% | 16,545.00% | 2,721.01% | -84.33% | -83.55% |
| SG&A Expenses | 29.15% | 82.25% | 71.74% | 74.49% | 86.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 384,835.06% | 13,944.00% | 1,521.58% | -- |
| Total Operating Expenses | 81.10% | 79.74% | 79.01% | 46.89% | 47.09% |
| Operating Income | 672.13% | 768.07% | 1,157.74% | -116.72% | -126.44% |
| Income Before Tax | 778.42% | 807.42% | 1,166.89% | -58.30% | -52.90% |
| Income Tax Expenses | 12,483.81% | 13,101.67% | 12,385.33% | 4.17% | 9.81% |
| Earnings from Continuing Operations | 728.17% | 753.45% | 1,094.80% | -58.70% | -53.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 728.17% | 753.45% | 1,094.80% | -58.70% | -53.35% |
| EBIT | 672.13% | 768.07% | 1,157.74% | -116.72% | -126.44% |
| EBITDA | 684.18% | 783.13% | 1,189.84% | -122.10% | -139.74% |
| EPS Basic | 688.66% | 682.86% | 959.96% | -37.19% | -29.92% |
| Normalized Basic EPS | 700.84% | 711.61% | 1,005.56% | -77.39% | -72.53% |
| EPS Diluted | 679.15% | 673.63% | 943.71% | -36.75% | -29.50% |
| Normalized Diluted EPS | 691.16% | 702.01% | 988.68% | -76.72% | -71.86% |
| Average Basic Shares Outstanding | 6.12% | 11.45% | 17.28% | 16.16% | 17.40% |
| Average Diluted Shares Outstanding | 6.49% | 11.84% | 16.77% | 15.23% | 16.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |